Ivan Topisirovic

Ivan Topisirovic

Auto-generated profile, based on publicly available information

Ivan Topisirovic

Department of Biochemistry, McGill University, Montreal, Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Cell Metabolism
Verified
Journal Article
Closed access
MMMasahiro Morita
Masahiro Morita
SGSimon-Pierre Gravel
Simon-Pierre Gravel
VCValérie Chénard
Valérie Chénard
KSKristina Sikström
Kristina Sikström
LZLiang Zheng
Liang Zheng
NSNahum Sonenberg
Nahum Sonenberg

6 March 2015 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MBMamatha Bhat
Mamatha Bhat
NRNathaniel Robichaud
Nathaniel Robichaud
LHLaura Hulea
Laura Hulea
NSNahum Sonenberg
Nahum Sonenberg
JPJerry Pelletier
Jerry Pelletier
ITIvan Topisirovic
Ivan Topisirovic

28 May 2010 in Science
Verified
Journal Article
Closed access
PDF file
RDRyan J. O. Dowling
Ryan J. O. Dowling
ITIvan Topisirovic
Ivan Topisirovic
TATommy Alain
Tommy Alain
MBMichael Bidinosti
Michael Bidinosti
BFBruno D. Fonseca
Bruno D. Fonseca
NSNahum Sonenberg
Nahum Sonenberg
Proliferation Control: The protein complex mTORC1, which contains the protein kinase known as mammalian target of rapamycin, is an important regulator of cell proliferation and cell size. Among many targets, mTORC1 phosphorylates the eukaryotic translation initiation factor eIF4E–binding proteins (4E-BPs), thus controlling translation of proteins that regulate proliferation. Dowling et al. (p. 1172 ) used mice lacking expression of the 4E-BPs to show that these proteins contribute to mTORC1's activation of cell proliferation, but are dispensable for the effects of mTORC1 on cell growth. The latter required another mTORC1 target—the ribosomal protein S6 kinase. mTORC1 inhibitors are being explored as potential anticancer agents, and the presence of 4E-BPs was necessary for mTORC1 inhibitors to reduce the number and size of colonies formed by transformed mouse cells.

16 February 2015 in Cell Cycle
Verified
Journal Article
Open access
MMMasahiro Morita
Masahiro Morita
SGSimon-Pierre Gravel
Simon-Pierre Gravel
LHLaura Hulea
Laura Hulea
OLOla Larsson
Ola Larsson
MPMichael Pollak
Michael Pollak
ITIvan Topisirovic
Ivan Topisirovic
Protein synthesis is one of the most energy consuming processes in the cell. The mammalian/mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that integrates a multitude of extrace...

28 October 2010 in WIREs RNA
Verified
Journal Article
Closed access
PDF file
ITIvan Topisirovic
Ivan Topisirovic
YSYuri V. Svitkin
Yuri V. Svitkin
NSNahum Sonenberg
Nahum Sonenberg
ASAaron J. Shatkin
Aaron J. Shatkin

2 July 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
DPDavid Papadopoli
David Papadopoli
KBKarine Boulay
Karine Boulay
LKLawrence Kazak
Lawrence Kazak
MPMichael Pollak
Michael Pollak
FMFrédérick Mallette
Frédérick Mallette
LHLaura Hulea
Laura Hulea
The mammalian/mechanistic target of rapamycin (mTOR) is a key component of cellular metabolism that integrates nutrient sensing with cellular processes that fuel cell growth and proliferation. Although the involvement of the mTOR pathway in regulating life span and aging has been studied extensively in the last decade, the underpinning mechanisms remain elusive. In this review, we highlight the emerging insights that link mTOR to various processes related to aging, such as nutrient sensing, maintenance of proteostasis, autophagy, mitochondrial dysfunction, cellular senescence, and decline in stem cell function.